Catequentinib Medicine 03 December 2024 Extended indication Catequentinib in combination with background chemotherapy for third line or later treatment of recurrent or metastatic cervical cancer, endometrial cancer, fallopian tube cancer, ovarian cancer, primary peritoneal carcinosarcoma in adults and elderly. Therapeutic value No estimate possible yet Total cost Registration phase Clinical trials Product Active substance Catequentinib Domain Oncology Reason of inclusion New medicine (specialité) Main indication Ovarian cancer Extended indication Catequentinib in combination with background chemotherapy for third line or later treatment of recurrent or metastatic cervical cancer, endometrial cancer, fallopian tube cancer, ovarian cancer, primary peritoneal carcinosarcoma in adults and elderly. Current proprietary name Already available biosimilars / generics Proprietary name Manufacturer Advenchen Portfolio holder Mechanism of action Route of administration Oral Therapeutical formulation Capsule Budgetting framework Intermural (MSZ) Centre of expertise Additional remarks RTK-remmer. Registration Registration route Centralised (EMA) Type of trajectory Normal trajectory Particularity ATMP No Submission date April 2026 Expected Registration May 2027 Orphan drug No Registration phase Clinical trials Reimbursement Medicine sluice Additional remarks Tijdslijn op basis van IHSI-inschatting. Therapeutic value Current treatment options Therapeutic value No estimate possible yet This assessment does not indicate any potential inclusion in the package. Substantiation Er is nog geen data beschikbaar. Duration of treatment Frequency of administration 1 times a day Dosage per administration 8mg References NCT02584478 (AL3818-US-002) Additional remarks Expected patient volume per year Patient volume Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References NKR 2022 (1). Additional remarks In 2022 was de incidentie van eierstok- en eileiderkanker 1.022, baarmoederlichaamkanker 486 en baarmoederhalskanker 335 patiënten, stadium III en IV (1). Hier komen ook nog de patiënten bij met primair peritoneaal carcinosarcoom, al is dit een zeldzame vorm van kanker. Ook zal het patiëntaantal afhangen van het aantal patiënten met terugkerende kanker. Aangezien dit een behandeling in de derde lijn betreft zal het patiëntvolume laag uitvallen. Expected cost per patient per year Cost References Additional remarks Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Indications off label use References Additional remarks Indication extension Indication extensions Indication extensions References Additional remarks Other information Additional remarks